Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Expectations By $0.11 EPS

Key Points

• Mixed Q1 results: Entrada reported a smaller-than-expected EPS loss (‑$0.95 vs. est. ‑$1.06) but missed revenue ($0.88M vs. est. $2.92M), and the stock plunged ~57.3% on heavy volume after the report.
• Clinical readout was double‑edged: Cohort 1 showed favorable safety and a statistically significant, clinically meaningful improvement in Time‑To‑Rise, but pediatric PK was ~50% lower than adults and dystrophin/exon‑skipping gains were modest, creating dosing and exposure uncertainty.
• Near‑term catalysts and runway: Cohort 2 (12 mg/kg) has been initiated with results expected by year‑end 2026, multiple other readouts planned in 2026, and management reports cash runway into Q3 2027.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.11, FiscalAI reports. The firm had revenue of $0.88 million for the quarter, compared to the consensus estimate of $2.92 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%.

Here are the key takeaways from Entrada Therapeutics' conference call:

• Favorable safety and tolerability at 6 mg/kg: no serious adverse events, mostly mild–moderate AEs (headache most common), normal kidney markers, and all eight Cohort 1 participants have moved into the open‑label period.
• Treated participants showed a statistically significant and clinically meaningful improvement in Time To Rise (TTR) velocity versus placebo (mean change 0.08 rises/sec, ~3.5× the MCID), with benefits across most patients despite the small sample size.
• Pediatric PK was ~50% lower than in healthy adult volunteers and adult NHPs, producing modest exon skipping (~2.3% above baseline) and low dystrophin at biopsy (≈2.3% then ~6% at day 127), creating exposure and dosing uncertainty that must be addressed.
• Updated modeling using juvenile NHP data projects a dose‑dependent, potentially non‑linear increase in plasma AUC/exon skipping; management expects double‑digit dystrophin in Cohort 2 (12 mg/kg) and higher in Cohort 3, with Cohort 2 dosing underway and results due by year‑end 2026.
• Pipeline and timing: Entrada highlights multiple near‑term catalysts (Cohort 1 open‑label and Cohort 2 readouts by year‑end 2026, ELEVATE‑45 Cohort 1 mid‑2026, partner DM1 data H2 2026) and a reported cash runway into the third quarter of 2027.

Entrada Therapeutics Stock Down 57.3%

TRDA traded down $9.18 during trading on Thursday, hitting $6.85. 4,118,062 shares of the company traded hands, compared to its average volume of 210,608. Entrada Therapeutics has a one year low of $4.93 and a one year high of $16.45. The stock's fifty day moving average is $12.82 and its 200 day moving average is $10.90. The firm has a market cap of $265.92 million, a P/E ratio of -1.98 and a beta of -0.09.

Wall Street Analysts Forecast Growth

TRDA has been the topic of several recent research reports. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. Oppenheimer upped their price target on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an "outperform" rating in a report on Monday, April 6th. Guggenheim upgraded Entrada Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 11th. Wall Street Zen lowered shares of Entrada Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Finally, Cantor Fitzgerald began coverage on shares of Entrada Therapeutics in a research report on Wednesday, April 1st. They set an "overweight" rating on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Entrada Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.

Entrada Therapeutics News Roundup

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Topline Cohort 1 results showed favorable safety/tolerability and a statistically significant improvement in Time‑to‑Rise velocity (an accepted functional measure) plus early increases in dystrophin and exon skipping — a clinical inflection that validates ENTR‑601‑44’s early activity. Read More.
• Positive Sentiment: Company has initiated Cohort 2 (12 mg/kg) based on PK modeling and expects additional cohort and open‑label data by year‑end 2026, creating multiple upcoming clinical catalysts. Read More.
• Neutral Sentiment: Q1 results: EPS loss of $0.95 beat the consensus of $1.06 (smaller loss), but revenue missed expectations ($0.88M vs. est. $2.92M). The EPS beat is modestly supportive, while the revenue miss underlines near‑term commercial/partnering headwinds. Read More.
• Negative Sentiment: Financials and cash flow concerns: Q1 net loss widened to $39.7M, collaboration revenue plunged (from $20.6M to $0.9M YoY), and cash declined to ~$255M — though management says runway into Q3 2027, the larger loss and falling collaboration receipts raise funding and execution risk. Read More.
• Negative Sentiment: Market reaction: despite the positive headline, investors sold aggressively (high volume) — likely driven by modest biomarker increases (dystrophin gains were small in absolute terms and juvenile PK was lower than adults), uncertainty about clinical dose/efficacy durability, and the earnings/revenue weakness. Read More.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 25,907 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.39, for a total transaction of $398,708.73. Following the completion of the transaction, the insider directly owned 216,317 shares of the company's stock, valued at approximately $3,329,118.63. This represents a 10.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Nathan J. Dowden sold 15,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.33, for a total value of $229,950.00. Following the transaction, the chief operating officer directly owned 198,588 shares of the company's stock, valued at approximately $3,044,354.04. This trade represents a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 82,882 shares of company stock worth $1,169,103 over the last three months. 9.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Several large investors have recently added to or reduced their stakes in TRDA. State of Wyoming lifted its holdings in Entrada Therapeutics by 130.9% during the second quarter. State of Wyoming now owns 7,575 shares of the company's stock valued at $51,000 after purchasing an additional 4,295 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock valued at $51,000 after buying an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new stake in shares of Entrada Therapeutics during the 2nd quarter valued at approximately $68,000. Jain Global LLC bought a new position in Entrada Therapeutics in the 3rd quarter worth approximately $69,000. Finally, IHT Wealth Management LLC purchased a new position in Entrada Therapeutics in the 2nd quarter valued at approximately $72,000. Hedge funds and other institutional investors own 86.39% of the company's stock.

About Entrada Therapeutics

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.